Revolution Medicines, Inc. (RVMD) Stock

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Revolution Medicines, Inc. is led by CEO Mark A. Goldsmith, employs 616 people, headquartered in Redwood City, US, publicly traded since 2020.

Revolution Medicines, Inc. (RVMD) stock trades at $188.07 with a market capitalization of $39.98B. The stock is valued at a price-to-earnings (P/E) ratio of -23.83, price-to-book of 18.48, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $34.00 and $193.50, and currently trades 2.8% below its 52-week high.

On profitability, Revolution Medicines, Inc. generates a return on equity (ROE) of -69.34%, return on capital employed of -72.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

In its most recent fiscal year, Revolution Medicines, Inc. reported annual revenue of $0, net profit of $-1.1B.

The balance sheet shows a debt-to-equity ratio of 0.10 — a conservative balance sheet with little leverage risk, a current ratio of 7.16, total assets of $2.4B, $384.0M in cash and equivalents.

RVMD has an average daily trading volume of 2,841,650 shares, a beta of 1.41 (more volatile than the overall market).

Official website: www.revmed.com